Clinical trials: in Greece
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
This study is intended to collect safety data from participants who completed the parent protocols but are still benefiting from study treatment.
- Trial name
- NCT05201066
- Testing
- decitabine, spartalizumab, sabatolimab
- Where
- 24 sites in United States, Australia and 13 more
- Volunteers
- 33 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
EVOLVE Study: The Real-life Clinical Practice With Tezepelumab in Greece
Tezepelumab is a first-in-class human monoclonal antibody for uncontrolled severe asthma that acts at the top of the inflammatory cascade by targeting thymic stromal lymphopoietin (TSLP), a key epithelial cytokine inducing both…
- Trial name
- EVOLVE (NCT06724575)
- Where
- 8 sites in Greece
- Volunteers
- 156 people
- Sponsor
- AstraZeneca
Active Idiopathic Inflammatory Myopathy, Myositis
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
This study's purpose is to measure the treatment response from efgartigimod PH20 SC compared with placebo in participants with Idiopathic Inflammatory Myopathy (IIM).
- Conditions
- Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis
- Trial name
- ALKIVIA (NCT05523167)
- Testing
- EFG PH20 SC, PBO
- Where
- 202 sites in United States, Argentina and 34 more
- Volunteers
- 265 people
- Sponsor
- argenx
Acute Ischemic Stroke
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
The goal of this study is to evaluate the safety and efficacy of JX10 versus placebo in participants with Acute Ischemic Stroke (AIS) who present for care within 4.5 to 24 hours. The main question the study aims to answer are: 1.
- Trial name
- ORION (NCT06990867)
- Testing
- JX10
- Where
- 104 sites in United States, Belgium and 19 more
- Volunteers
- 740 people
- Sponsor
- Corxel Pharmaceuticals
Frontotemporal Dementia
A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)
A phase 3 double blind, placebo controlled study evaluating the efficacy and safety of AL001 in participants at risk for or with frontotemporal dementia due to heterozygous mutations in the progranulin gene.
- Trial name
- NCT04374136
- Testing
- Part 1 Blinded - AL001, Part 2 (OLE Treatment) - AL001
- Where
- 44 sites in United States, Argentina and 14 more
- Volunteers
- 119 people
- Sponsor
- Alector Inc.
End Stage Kidney Disease
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1: Phase 2b is a dose-finding study for CSL300 vs placebo.
- Trial name
- POSIBIL6ESKD (NCT05485961)
- Testing
- CSL300
- Where
- 566 sites in United States, Argentina and 33 more
- Volunteers
- 3,110 people
- Sponsor
- CSL Behring
Non-Small Cell Lung Cancer
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
- Trial name
- HARMONi-7 (NCT06767514)
- Testing
- Ivonescimab Injection, Pembrolizumab Injection
- Where
- 285 sites in United States, Belgium and 15 more
- Volunteers
- 780 people
- Sponsor
- Summit Therapeutics
Heterozygous or Homozygous Familial Hypercholesterolemia
Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies
The purpose of this open-label, single arm, multicenter extension study is to evaluate the long-term safety and tolerability of inclisiran in participants with HeFH or HoFH who have completed the ORION-16 (CKJX839C12301)…
- Trial name
- V-PEDS-OLE (NCT05682378)
- Testing
- Inclisiran
- Where
- 52 sites in United States, Argentina and 24 more
- Volunteers
- 195 people
- Sponsor
- Novartis Pharmaceuticals
Haemophilia A and B With and Without Inhibitors
A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors
This study will test how well a new medicine called concizumab works for participants who have haemophilia A or B with or without inhibitors. The purpose is to show that concizumab can prevent bleeds and is safe to use.
- Trial name
- Explorer10 (NCT05135559)
- Testing
- Concizumab
- Where
- 91 sites in United States, Algeria and 22 more
- Volunteers
- 153 people
- Sponsor
- Novo Nordisk A/S
Sickle Cell Disease, Thalassemia
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin.
- Trial name
- FLORAL (NCT06609226)
- Testing
- Etavopivat A, Etavopivat B, Etavopivat C
- Where
- 107 sites in United States, Canada and 15 more
- Volunteers
- 480 people
- Sponsor
- Novo Nordisk A/S
Chronic Obstructive Pulmonary Disease
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
This is a parallel, double blind, Phase 3, 2-arm study that is designed to provide additional safety information, assess the durability of treatment response, and provide additional PK and immunogenicity assessments.
- Trial name
- AERIFY-4 (NCT06208306)
- Testing
- Itepekimab (SAR440340)
- Where
- 223 sites in United States, Argentina and 30 more
- Volunteers
- 669 people
- Sponsor
- Sanofi
Endometrial Neoplasms
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
The purpose of this study is to compare pembrolizumab + adjuvant chemotherapy with placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to disease-free survival (DFS) as assessed radiographically by the…
- Trial name
- NCT04634877
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- 231 sites in United States, Argentina and 26 more
- Volunteers
- 990 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement [N2])…
- Trial name
- INTerpath-002 (NCT06077760)
- Testing
- Intismeran autogene, Pembrolizumab
- Where
- 229 sites in United States, Argentina and 31 more
- Volunteers
- 868 people
- Sponsor
- Merck Sharp & Dohme LLC
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
Phase 2b Study of GSK4532990 in Adults With NASH
The purpose of this study is to measure improvements in liver fibrosis and inflammation with GSK4532990 compared with placebo in participants with NASH and advanced fibrosis on biopsy (F3 or F4).
- Trial name
- HORIZON (NCT05583344)
- Testing
- GSK4532990
- Where
- 170 sites in United States, Argentina and 15 more
- Volunteers
- 284 people
- Sponsor
- GlaxoSmithKline
Ulcerative Colitis
Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis
The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in ulcerative…
- Trial name
- SELECTIONLTE (NCT02914535)
- Testing
- Filgotinib
- Where
- 323 sites in United States, Argentina and 37 more
- Volunteers
- 1,173 people
- Sponsor
- Alfasigma S.p.A.
Sickle Cell Disease
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle…
- Trial name
- Hibiscus 2 (NCT06612268)
- Testing
- Etavopivat
- Where
- 175 sites in United States, Australia and 19 more
- Volunteers
- 510 people
- Sponsor
- Novo Nordisk A/S
Relapsing Multiple Sclerosis
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS.
- Trial name
- FENhance 2 (NCT04586023)
- Testing
- Fenebrutinib, Teriflunomide
- Where
- 106 sites in United States, Austria and 15 more
- Volunteers
- 751 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis, Primary Progressive
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
A study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS).
- Trial name
- FENtrepid (NCT04544449)
- Testing
- Fenebrutinib, Ocrelizumab
- Where
- 190 sites in United States, Argentina and 26 more
- Volunteers
- 985 people
- Sponsor
- Hoffmann-La Roche
Multiple Myeloma
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma…
- Trial name
- NCT05827016
- Testing
- Iberdomide, Lenalidomide
- Where
- 269 sites in United States, Argentina and 32 more
- Volunteers
- 1,230 people
- Sponsor
- Bristol-Myers Squibb
Obesity, Overweight
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral…
- Conditions
- Obesity, Overweight, Chronic Weight Management, Type 2 Diabetes Mellitus
- Trial name
- AURORA-2 (NCT07743450)
- Testing
- ASC30 tablets A1
- Where
- 135 sites in United States, Czechia and 4 more
- Volunteers
- 1,560 people
- Sponsor
- Ascletis Pharma (China) Co., Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.